|
 |
Cutaneous T-Cell LymphomaThis page contains recent news articles, when available, and an overview of Cutaneous T-Cell Lymphoma but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.News: Cutaneous T-Cell Lymphoma Washington PostBy Steven Reinberg. THURSDAY, July 19 (HealthDay News) -- The incidence of a rare cancer called cutaneous T-cell lymphoma has increased threefold over the ... Istodax Approved for Cutaneous T-Cell Lymphoma - Nov 6, 2009 ForbesFRIDAY, Nov. 6 (HealthDay News) -- The Gloucester Pharmaceuticals drug Istodax (romidepsin) has been approved by the US Food and Drug Administration to ... Celgene to Acquire Gloucester Pharmaceuticals - Dec 7, 2009 MarketWatchCelgene Corporation (NASDAQ:CELG) and Gloucester Pharmaceuticals Inc., a privately held pharmaceutical company, announced a definitive merger agreement ... … Sezary syndrome is a unique cutaneous T-cell lymphoma as identified... - Nov 22, 2007 Nature.comClassification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477–1488. ... Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell ... - Feb 29, 2008 Nature.comCorrespondence: Dr KL Grogg, MD, Department of Laboratory Medicine and Pathology, 200 1st Street SW, Mayo Clinic, Rochester, MN 55905, USA. ... … Trial with FK228 in Cutaneous T-Cell Lymphoma; FDA Approves Trial... - Mar 1, 2005 Free with registration - Business Wire - AccessMyLibrary.comCAMBRIDGE, Mass. -- Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that it has initiated a ... FDA Approves Zolinza for Cutaneous T-cell Lymphoma - Oct 9, 2006 MedPage TodayBy Peggy Peck, Managing Editor, MedPage Today. ROCKVILLE, Md., Oct. 9 -- The FDA has approved Zolinza (vorinostat) capsules as second-line therapy for ... FDA Approves Zolinzaâ„¢ for Treatment of Cutaneous T-Cell Lymphoma - Oct 6, 2006 Cancer ConsultantsOn October 6, 2006, the US Food and Drug Administration approved Zolinza (vorinostat) for the treatment of the cutaneous manifestations of cutaneous T-cell ... Allos Therapeutics' FOLOTYN(TM) Shows Activity in a Dose Finding … - Dec 8, 2009 Wall Street JournalAllos Therapeutics, Inc. (NASDAQ: ALTH) today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN(TM) (pralatrexate injection) in ... Cutaneous T-cell lymphoma becomes more common in US - Jul 17, 2007 News-Medical.netThe cancer known as cutaneous T-cell lymphoma became substantially more common in the United States between 1973 and 2002, according to a report in the July ... Clinicopathological Characterization and Genomic Aberrations in … - Mar 13, 2008 Nature.com...(2006) Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res 12:4812–4821 | Article | PubMed | ChemPort | ... FDA approves vorinostat for cutaneous T-cell lymphoma: Orphan drug is... - Nov 1, 2006 Free with registration - Skin & Allergy News - AccessMyLibrary.comThe Food and Drug Administration approved a new drug for the treatment of refractory or recurrent cutaneous T-cell lymphoma, the agency announced in a ... Article: Cutaneous T-cell lymphoma deaths are often misreported.(Clini... - Aug 1, 2007 Pay-Per-View - Skin & Allergy News - HighBeam ResearchCutaneous T-cell lymphoma deaths are often misreported.(Clinical Rounds) ... find Skin & Allergy News articles. LOS ANGELES -- Fewer than half of deaths ... Turmeric induces apoptosis in cutaneous T-cell lymphoma.(Clinical … - Jul 1, 2006 Pay-Per-View - Skin & Allergy News - HighBeam ResearchTurmeric induces apoptosis in cutaneous T-cell lymphoma.(Clinical Rounds) ... find Skin & Allergy News articles. PHILADELPHIA -- Curcumin, the compound that ... Source of molecular triggers in cutaneous T cell lymphoma identified - Feb 26, 2005 PsychCentral.comNew Haven, Conn. -- In a study published in the journal Blood, Yale scientists identify the molecular triggers that stimulate Cutaneous T Cell Lymphoma ... JP Morgan starts Allos Therapeutics with overweight - Jan 8, 2010 Reuters UKData from the lung cancer trial and the cutaneous T cell lymphoma are expected to be available in the first half of 2010. ... … Romidepsin Approval for Cutaneous T-cell Lymphoma | Article from W - Sep 8, 2009 Pay-Per-View - Wireless News - HighBeam ResearchFDA Advisory Committee Endorses Gloucester's Romidepsin Approval for Cutaneous T-cell Lymphoma ... find Wireless News articles. Wireless News 09-08-2009 FDA ... Ontak for cutaneous T-cell lymphoma - Apr 11, 2008 ecancermedicalscienceOn October 15, 2008, the US Food and Drug Administration converted the approval of denileukin diftitox (Ontak) solution, for intravenous use for the ... … : FDA approves vorinostat for cutaneous T-cell lymphoma: Orphan... - Nov 1, 2006 Pay-Per-View - Skin & Allergy News - HighBeam ResearchFDA approves vorinostat for cutaneous T-cell lymphoma: Orphan drug is the first histone deacetylase inhibitor; the disease afflicts 3 in 1 million people. PUVA Induces Long-Term Remissions with Cutaneous T-Cell Lymphoma - Mar 21, 2005 Cancerpage.comNEW YORK MAR 21, 2005 (Reuters Health) - Treatment with psoralen plus UV-A (PUVA) can induce long-term remissions in patients with early stage mycosis ... … ' ISTODAX® for Patients with Cutaneous T-cell Lymphoma - Nov 5, 2009 Genetic Engineering News - Genetic Engineering News (press release)Gloucester Pharmaceuticals announced today that the US Food and Drug Administration (FDA) approved ISTODAX ® (romidepsin) for the treatment of cutaneous ... BioCryst's CTCL Pivotal Study Achieves Enrollment Target - Jan 15, 2010 Wall Street JournalBIRMINGHAM, Ala., Jan. 15 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has achieved its ... Article: Cutaneous T-cell lymphoma incidence rising.(Cutaneous … - Jun 1, 2008 Pay-Per-View - Skin & Allergy News - HighBeam ResearchCutaneous T-cell lymphoma incidence rising.(Cutaneous Oncology) ... find Skin & Allergy News articles. WAIKOLOA, HAWAII -- The incidence of cutaneous T-cell ... Cutaneous T-cell lymphoma deaths are often misreported.(Clinical … - Aug 1, 2007 $4.95 - Skin & Allergy News - ECNextLOS ANGELES -- Fewer than half of deaths attributable to cutaneous T-cell lymphoma are listed as such on death certificates, Dr. David A. Barzilai said at ... Allos Therapeutics Announces New Data on FOLOTYN(TM) to be … - Nov 11, 2009 Wall Street JournalAllos Therapeutics, Inc. (Nasdaq: ALTH) today announced that abstracts from studies of FOLOTYN(TM) (pralatrexate injection) were accepted for presentation ... … ' Development of Romidepsin for Cutaneous T-Cell Lymphoma Continues... - Mar 29, 2007 Genetic Engineering News - Genetic Engineering News (press release)Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, today announced that following a planned safety review by an independent ... … ; Company initiates pivotal trial with FK228 in cutaneous t-cell... - Mar 29, 2005 Pay-Per-View - Science Letter - Factiva, from Dow Jones2005 MAR 29 - (NewsRx.com) -- Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced that it has initiated a ... Article: Gene therapy promising for cutaneous lymphoma.(Cutaneous … - Sep 1, 2008 Pay-Per-View - Skin & Allergy News - HighBeam ResearchCancer Weekly; February 18, 2003 ; 700+ words ... ... in cutaneous T cell lymphoma lesions along ... in Journal of Investigative Dermatology (Increased CCR4 ... Study of ONTAK (denileukin diftitox) in cutaneous T-cell lymphoma... - Jan 1, 2006 Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.comThis study is currently recruiting patients. Sponsored by Ligand Pharmaceuticals. The purpose of this study is to compare the effectiveness of 2 dose levels ... Press Release: Serono and Genmab Announce Global Development and … - Aug 18, 2005 Pay-Per-View - PR Newswire - HighBeam ResearchSerono and Genmab Announce Global Development and Commercialization Agreement for Humax-CD4. from PR Newswire. Highbeam Research – FREE Trial. YAUPON ENROLLS PHASE 2 OF CLEARAZIDE FOR T-CELL … - Aug 1, 2009 Pay-Per-View - Biotech Business - HighBeam Research..."Cutaneous T-cell lymphoma, like all cancers, is a terrible burden on families ... Cutaneous T-cell lymphoma is a cancer of the T-lymphocytes in the skin. ... … (denileukin diftitox) in previously treated cutaneous T-cell... - Apr 1, 2006 Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.comThis study is currently recruiting patients. Sponsored and verified by Ligand Pharmaceuticals. The purpose of this study is to provide an opportunity for ... Cutaneous t-cell lymphoma incidence on the rise.(Oncology) - Sep 1, 2007 $4.95 - Dermatology Times - ECNextThe incidence of cutaneous T-cell lymphoma is on the rise in the United States, but the reason for this escalation is unknown, according to a report in the ... Cutaneous T Cell Lymphoma; HuMax-CD4 shows encouraging duration … - Mar 15, 2005 Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones2005 MAR 15 - (NewsRx.com) -- Genmab A/S announced additional encouraging duration of response data from one of its HuMax-CD4 (zanolimumab) phase II studies ... Graft-versus-adult T-cell leukemia/lymphoma effect following allogenei... - Mar 10, 2008 Nature.comCorrespondence: Dr A Utsunomiya, Department of Hematology, Imamura Bun-in Hospital, 11-23 Kamoikeshinmachi, Kagoshima 890-0064, Japan. ... FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma - Nov 12, 2009 Medical News Today - Medical News Today (press release)The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma ... … ; Company initiates pivotal trial with FK228 in cutaneous t-cell... - Apr 3, 2005 Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones2005 APR 3 - (NewsRx.com) -- Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced that it has initiated a ... Article: Treatment of cutaneous T-cell lymphoma/mycosis fungoides.( … - Dec 1, 2006 Pay-Per-View - Dermatology Nursing - HighBeam ResearchTreatment of cutaneous T-cell lymphoma/mycosis fungoides.(Disease Management)(Disease/Disorder overview) ... find Dermatology Nursing articles. Gloucester Pharmaceuticals Announces Podium Presentation of Positive ... - Jun 5, 2008 RedOrbitGloucester Pharmaceuticals today announced that its late-stage product candidate, romidepsin, was the subject of a podium presentation entitled ... On the rise: cutaneous T-cell lymphoma incidence increases.(News) - Aug 1, 2007 $4.95 - Dermatology Times - ECNextProvidence, RI -- The incidence of cutaneous T-cell lymphoma (CTCL) has increased steadily over the last three decades, according to a new study published ... New primary cutaneous B-cell lymphoma guidelines highlight differentia... - Apr 1, 2009 Pay-Per-View - Skin & Allergy News - HighBeam ResearchNew primary cutaneous B-cell lymphoma guidelines highlight differential diagnosis.(CUTANEOUS ONCOLOGY) ... find Skin & Allergy News articles. Lou Gehrig had nothing on her - Iron lady who beat a rare cancer... - Apr 13, 2008 $2.95 - Philadelphia Inquirer - NewsBankIron lady who beat a rare cancer turned to triathlon competition to help herself as well as others. A Pottstown woman with a rare illness called cutaneous ... Serono and Genmab Announce Global Development and … - Aug 18, 2005 Free with registration - PR Newswire - AccessMyLibrary.comGENEVA, Switzerland and COPENHAGEN, Denmark, August 18 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) and Genmab A/S announced today an ... Press Release: Genmab Initiates Ofatumumab Phase II Study in Diffuse ... - Dec 13, 2007 Pay-Per-View - PR Newswire - HighBeam ResearchGenmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma. from PR Newswire. Highbeam Research – FREE Trial. Treatment of cutaneous T-cell lymphoma/mycosis fungoides.(Disease … - Dec 1, 2006 $4.95 - Dermatology Nursing - ECNextLymphomas are traditionally classified as Hodgkins or non-Hodgkins lymphomas. Within the spectrum of non-Hodgkin lymphomas (NHL), lymphomas are further ... Rituximab clears B-cell lymphoma skin lesions.(CUTANEOUS … - May 1, 2009 Pay-Per-View - Skin & Allergy News - HighBeam ResearchRituximab clears B-cell lymphoma skin lesions.(CUTANEOUS ONCOLOGY) ... find Skin & Allergy News articles. SAN FRANCISCO -- Intralesional rituximab appears ... … -CD4(TM) in Non-Cutaneous T-Cell Lymphoma. - PR Newswire Eu - Dec 12, 2005 Pay-Per-View - PR Newswire Europe - HighBeam ResearchPR Newswire; September 1, 2004 ; 700+ words ... ... announced today that cutaneous T-cell lymphoma (CTCL) patients in the HuMax-CD4 Phase II studies ... … Initiates Study Of PDX In Patients With Cutaneous T-Cell Lymphoma - Aug 16, 2007 Medical News Today - Medical News Today (press release)Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of the Company's ... Press Release: Yaupon Therapeutics Completes Patient Enrollment for … - Jun 29, 2009 Pay-Per-View - PR Newswire - HighBeam ResearchYaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma. from PR Newswire. Press Release: FDA Grants Orphan Drug Designation to Allos … - Jul 26, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchStudy patients ... patients with cutaneous T-cell lymphoma (CTCL) and for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan ... Press Release: Genmab Initiates Ofatumumab Phase II Study in Diffuse ... - Dec 13, 2007 Pay-Per-View - PR Newswire Europe - HighBeam ResearchGenmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma. from PR Newswire Europe. Highbeam Research – FREE Trial. Gloucester Pharmaceuticals to Present Positive Results from Multiple ... - Nov 20, 2008 International Business TimesGloucester Pharmaceuticals today announced four presentations from clinical trials of romidepsin at the upcoming 50 th American Society of Hematology (ASH) ... Summary and Introduction - Nov 21, 2005 MedscapeFollowing consensus meetings of the two parent organizations, a new World Health Organization–European Organization for Research and Treatment of Cancer ... Derm Dx.(Skin Disorders)(B-cell lymphoma) | Article from Family... - Apr 1, 2006 Pay-Per-View - Family Practice News - HighBeam ResearchDerm Dx.(Skin Disorders)(B-cell lymphoma) ... find Family Practice News articles. An 88-year-old white man with a history of non-melanoma skin cancer ... Arch Dermatol -- CD8+ Epidermotropic Cytotoxic T-Cell Lymphoma With … - Dec 28, 2007 Archives of DermatologyYou are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you ... Press Release: Investigational Targeted Therapy May Offer Progress... - Dec 10, 2005 Pay-Per-View - PR Newswire Europe - HighBeam ResearchInvestigational Targeted Therapy May Offer Progress For Non-Hodgkin's Lymphoma Patients. from PR Newswire Europe. Highbeam Research – FREE Trial. Gloucester Pharmaceuticals Presents Positive Clinical Data for … - Jun 1, 2009 Genetic Engineering News - Genetic Engineering News (press release)Gloucester Pharmaceuticals today announced presentations of two studies of romidepsin, its novel, cyclic peptide, histone deacetylase inhibitor under ... Article: New drugs show promise for CTCL treatment.(News) - Skin & … - Sep 1, 2008 Pay-Per-View - Skin & Allergy News - HighBeam ResearchArticle: Turmeric induces apoptosis in cutaneous T-cell lymphoma. ... Patients with cutaneous T-cell lymphoma (CTCL) face numerous problems in which ... Press Release: CuraGen and TopoTarget Initiate Phase II Clinical... - Feb 1, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchCuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma. from PR Newswire. Highbeam Research – FREE Trial. Forodesine HCl for cutaneous T cell lymphoma.(PIPELINE PREVIEWS)( … - Dec 1, 2007 $4.95 - Journal of Drugs in Dermatology - ECNextBioCryst Pharmaceuticals, Inc recently announced that patient enrollment has begun for its clinical trial of forodesine HCl in the treatment of cutaneous T ... Two Pralatrexate Studies Presented at the 50th Annual Meeting of the ... - Dec 6, 2008 Genetic Engineering News - Genetic Engineering News (press release)Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that results from two pralatrexate (PDX) studies were presented as posters during the 50 th Annual ... Cutaneous B-cell lymphoma tied to infection in Europe.(Clinical... - Dec 1, 2005 Pay-Per-View - Skin & Allergy News - HighBeam ResearchCutaneous B-cell lymphoma tied to infection in Europe.(Clinical Rounds) ... find Skin & Allergy News articles. LONDON -- Tick-borne Borrelia burgdorferi, ... Genmab Reveals Positive Results From Two Lymphoma Studies - Dec 11, 2006 RedOrbitGenmab has revealed positive early results from two studies evaluating HuMax-CD4 in both cutaneous and non-cutaneous T-cell lymphoma. ... Phase II study of sapacitabine for advanced cutaneous T cell lymphoma.... - Jul 1, 2007 $4.95 - Journal of Drugs in Dermatology - ECNext...it has started a multicenter randomized phase II clinical trial of sapacitabine (CYC682) for the treatment of advanced cutaneous T cell lymphoma (CTCL). ... Absence of HTLV-Related Sequences in Skin Lesions and Peripheral … - May 14, 2009 Nature.comPancake BA, Zucker-Franklin D, Coutavas EE (1995) The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. ... Press Release: Genmab Announces Early Results of Ongoing HuMax- … - Dec 10, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchGenmab Announces Early Results of Ongoing HuMax-CD4 Trials. from PR Newswire. Highbeam Research – FREE Trial. Allos Therapeutics Reports 2008 Third Quarter Results - Nov 5, 2008 Genetic Engineering News - Genetic Engineering News (press release)Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the third quarter of 2008. For the three months ended September 30, 2008, ... Genmab Shares Rise After Trial Amended, Bank Resumes Coverage - Oct 11, 2007 BloombergBy Frances Schwartzkopff. Oct. 11 (Bloomberg) -- Genmab A/S, the Danish biotechnology company developing cancer drugs, rose the most in 10 months after ... Gloucester Pharmaceuticals to Present Positive Results from Multiple ... - Nov 24, 2009 earthtimes.orgCAMBRIDGE, Mass. - (Business Wire) Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX ... Graft versus lymphoma effect after early relapse following reduced- … - Jun 25, 2007 Nature.comA 45-year-old man was diagnosed with a cytotoxic (CD8+ve CD56+ve TIA-1+ve) variant of mycosis fungoides (MF) stage IB, in 2002. He presented with patches ... Gloucester Pharmaceuticals Reports on Data From Clinical Studies … - May 24, 2005 RedOrbitGloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today reported on data from two separate clinical trials of its ... Gloucester Pharmaceuticals Announces Positive Results From Phase 2b … - May 19, 2008 RedOrbitGloucester Pharmaceuticals today announced the presentation of positive data from a Phase 2b registration trial of romidepsin in patients with advanced ... … Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma.... - Aug 15, 2007 Pay-Per-View - PR Newswire - HighBeam ResearchAllos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma. from PR Newswire. Highbeam Research – FREE Trial. Press Release: ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall ... - Jun 4, 2007 Pay-Per-View - PR Newswire - HighBeam ResearchONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL). from PR Newswire. … Fodosine(TM) for the Treatment of Cutaneous T-Cell Lymphoma - Feb 6, 2007 Free with registration - PR Newswire - AccessMyLibrary.comBIRMINGHAM, Ala., Feb. 6 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that Fodosine(TM) has been granted orphan status for the ... Gloucester Pharmaceuticals Reports Clinically Significant Responses... - Dec 10, 2007 Genetic Engineering News - Genetic Engineering News (press release)Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that preliminary results from the pivotal trial ... Gloucester Pharmaceuticals Reports Clinically Significant Responses... - Dec 12, 2006 Free with registration - Business Wire - AccessMyLibrary.comCAMBRIDGE, Mass. -- Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today interim data for romidepsin ... Press Release: Genmab Announces Early Results of Ongoing HuMax- … - Dec 10, 2006 Pay-Per-View - PR Newswire Europe - HighBeam ResearchGenmab Announces Early Results of Ongoing HuMax-CD4 Trials. from PR Newswire Europe. Highbeam Research – FREE Trial. Press Release: Chemotherapy Consolidation with Zevalin(R) (90Y- … - Dec 12, 2005 Pay-Per-View - PR Newswire Europe - HighBeam ResearchChemotherapy Consolidation with Zevalin(R) (90Y-Ibritumomab tiuxetan) May Provide Therapeutic Benefit for Mantle Cell Lymphoma Patients. from PR Newswire ... NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New … - Nov 23, 2009 FOXBusinessFORT WASHINGTON, Pa., Nov 23, 2009 /PRNewswire-USNewswire via COMTEX/ ----Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL) ... Gloucester Pharmaceuticals Announces Positive Results from Phase 1/2 ... - Dec 9, 2008 International Business TimesGloucester Pharmaceuticals yesterday announced positive interim results from a Phase 1/2 combination study of romidepsin, Velcade ® (bortezomib) and ... Genmab says its new HuMax-CD4 drug has unique action to treat cancer - Oct 15, 2007 ForbesCOPENHAGEN (Thomson Financial) - Genmab AS said its its HuMax-CD4 (zanolimumab), a potential cancer treatment currently being developed to treat cutaneous ... Danish shares close lower, led down by Torm, AP Moller; Norden higher... - Oct 15, 2007 ForbesThe group said its HuMax-CD4 (zanolimumab), a potential cancer treatment currently being developed to treat cutaneous T-cell lymphoma and non-cutaneous ... Data Safety Monitoring Board Recommends Continuation of Gloucester … - Apr 26, 2006 Genetic Engineering News - Genetic Engineering News (press release)Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that an independent Data Safety Monitoring Board ... Press Release: Interim Response and Safety Analyses Support … - Sep 24, 2007 Pay-Per-View - PR Newswire - HighBeam ResearchInterim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell ... Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 ... - Jun 29, 2009 RedOrbitRADNOR, Pa. , June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for ... Combo Tx for CTCL may delay need for chemo.(Dermatologic Therapy) | … - Jun 1, 2006 Pay-Per-View - Skin & Allergy News - HighBeam ResearchCombo Tx for CTCL may delay need for chemo.(Dermatologic Therapy) ... find Skin & Allergy News articles. KOLOA, HAWAII -- Dermatologic treatment algorithms ... Press Release: Results Reported at the American Society of Hematology... - Dec 11, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchResults Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel Antifolate PDX in Patients ... vorinostat Merck & Co clinical data (phase II) (T-cell lymphoma)... - Jun 19, 2006 Pay-Per-View - R & D Focus Drug News - Factiva, from Dow JonesDuring this single-arm, non-randomized trial, 74 patients with advanced, refractory cutaneous T-cell lymphoma (CTCL) who had previously failed a median of ... Press Release: Wyeth's Torisel Approved by European Commission for … - Aug 27, 2009 Pay-Per-View - PR Newswire Europe - HighBeam ResearchWyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma. from PR Newswire Europe. Roanoke Fire-EMS battalion chief retires - Oct 25, 2006 Roanoke TimesBilly Obenchain will retire soon after 33 years of service with the Roanoke Fire-EMS Department. By Amanda Codispoti. Battalion Chief Billy Obenchain won't ... Article: Think infection in primary cutaneous B-cell lymphomas.(Clinic... - Mar 1, 2005 Pay-Per-View - Skin & Allergy News - HighBeam ResearchThink infection in primary cutaneous B-cell lymphomas.(Clinical Rounds) ... find Skin & Allergy News articles. VIENNA -- Routine screening for evidence of ... Gloucester Reports Positive Results From Phase II Study of Lymphoma … - Jun 18, 2008 RedOrbitThe study conducted by the US National Cancer Institute is a seven-arm, Phase II, open-label trial of romidepsin in patients with cutaneous T-cell lymphoma ... Rituximab may be useful adjunct in B-cell lymphoma.(Hematology)(Brief... - Mar 15, 2007 Pay-Per-View - Internal Medicine News - HighBeam ResearchRituximab may be useful adjunct in B-cell lymphoma.(Hematology)(Brief article) ... find Internal Medicine News articles. ORLANDO -- Rituximab improves ... The many treatment faces of CTCL: challenges hinder recognition, … - Mar 1, 2007 $4.95 - Dermatology Times - ECNextWashington -- Dermatologists are occasionally confronted with a difficult-to-treat rash that is recalcitrant to standard therapies, and these sometimes ... Favrille Announces FDA Allowance Of Investigational New Drug … - Jun 16, 2006 Medical News Today - Medical News Today (press release)Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer, announced today that its ... BioCryst Receives Special Protocol Assessment for Pivotal Trial of... - Jul 9, 2007 Free with registration - PR Newswire - AccessMyLibrary.comBIRMINGHAM, Ala., July 9 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that it has reached an agreement with the US Food and Drug ... Gloucester Pharmaceuticals to Present Interim Pivotal Clinical Trial... - May 30, 2006 Genetic Engineering News - Genetic Engineering News (press release)Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that interim data from the Company's pivotal ... Telegram.com - A product of the Worcester Telegram & Gazette - Dec 15, 2009 Worcester Telegram - Worcester Telegram...on short-term Treasury bills were mixed in Monday's auction. Rates on three-month bills dropped to the lowest level in two weeks, while rates on six-month ... B -- STUDY OF DEPSIPEPTIDE IN PATIENTS -AUSTRALIA - Aug 28, 2006 Pay-Per-View - FedBizOpps - Factiva, from Dow JonesThe National Cancer Institute (NCI), Center for Cancer Research (CCR) plans to procure on a sole source basis, services regarding: Phase II study of ... Background information on Cutaneous T-Cell Lymphoma [When available] Cutaneous T-Cell lymphoma (CTCL) is a class of non-Hodgkin's lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin's lymphomas (which are generally B-cell related), CTCL is caused by a mutation of T cells. The malignant T cells in the body are pushed to the surface of the skin in a biological process used to rid the body of offending material, causing various lesions to appear on the skin. These lesions change shape as the disease progresses, typically beginning as what appears to be a rash and eventually forming plaques and tumors before metastatizing to other parts of the body. Though there are many types of CTCL and presentation can vary from individual to individual, there are two main forms: mycosis fungoides (MF) and Sézary syndrome (SS). There is some dispute over whether SS is an advanced form of MF or a different type of CTCL entirely -- in either case, the prognosis for SS patients is substantially poorer than for those of MF. There is no cure for CTCL, but there are a variety of treatment options available and most (about 90%) of CTCL patients are able to live relatively normal lives without serious, health-compromising complications. Search the web for more resources on Cutaneous T-Cell Lymphoma |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
